Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes.
Peters
Anne L
AL
The University of Southern California, Clinical Diabetes Programs, Los Angeles, California (Dr Peters)
Miller
Donna
D
The USC Westside Center for Diabetes, Beverly Hills, California (Ms Miller)
D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D000077270:Exenatide; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
D001786:Blood Glucose; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms